+200%

est. 2Y upside i

InsurTechSeries A

Private sector Healthcare.gov.

Rank

#50

Sector

InsurTech

Est. Liquidity

~3Y

Data Quality

Data: Low

The equity opportunity offers a high expected upside of ~200% over 2 years, driven by a low entry valuation and strong market position.

Last updated: July 3, 2026

Bull (15%)+100%

IPO window opens, capitalizing on HealthSherpa's EDE leadership and profitability. Exit multiple capped at 0.72x forward revenue, yielding 100% upside.

Base (55%)+315%

Steady revenue growth to $150M, multiple expands to 1.5x (in line with public comps), resulting in 315% upside.

Bear (30%)+38%

Regulatory headwinds and incumbent competition compress multiple to 0.5x, with flat revenue. Upside limited to 38%.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

937%

$9.37M in liquidation preference, representing 17% of current valuation, moderate risk.

Dilution Risk

low

Company is profitable and capital-efficient; no near-term funding needs expected.

Secondary Liquidity

none

No secondary market activity detected; equity is illiquid until exit.

Other — 1 role

People & Talent — 1 role

View all 2 open roles at HealthSherpa →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on HealthSherpa's data — designed to show you've done your homework.

  • 1

    “How will recent CMS rule changes impact HealthSherpa's growth trajectory and agent network?”

  • 2

    “What are the key assumptions behind the commission-based revenue model's sustainability amid regulatory shifts?”

  • 3

    “Given the 2018 valuation, how does the current equity value align with the company's financial performance?”

Community

Valuation Sentiment

Our model estimates +200% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.